| Bioactivity | Amivantamab (JNJ-61186372) is a human EGFR-MET bispecific antibody with immune anticancer activity. Amivantamab inhibits ligand binding, promotes endocytosis and degradation of receptor-antibody complexes, and induces Fc-dependent cytokinesis in macrophages and antibody-dependent cytotoxicity in natural killer cells[1]. |
| Invitro | Amivantamab (JNJ-61186372)(0.05-1 mg/mL) 导致 Ba/F3 细胞活力显着且剂量依赖性降低，EGFR 下游信号通路磷酸化 EGFR (pEGFR)、磷酸化 AKT (pAKT)、磷酸化 ERK (pERK) 和磷酸化 S6 (pS6) 也显着降低[2]。Amivantamab (JNJ-61186372) 可以通过下调 EGFR 和 MET 信号通路在具有 EGFR Exon20ins 突变的 NSCLC 患者来源的癌细胞中具有有效的抗肿瘤活性[2]。 |
| In Vivo | Amivantamab (JNJ-61186372) (i.p, 30 mg/kg, twice a week, 15 days) 可以有效减小在雌性无胸腺 BALB-c/nu 小鼠的 EGFR Exon20ins 突变的 NSCLC 异种移植模型中的肿瘤体积，具有体内抗肿瘤作用[2]。 |
| Name | Amivantamab |
| CAS | 2171511-58-1 |
| Appearance | Liquid |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Keunchil Park, et al. Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study. J Clin Oncol. 2021 Oct 20;39(30):3391-3402. [2]. Jiyeon Yun, et al. Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion-Driven NSCLC. Cancer Discov. 2020 Aug;10(8):1194-1209. |